Literature DB >> 11844605

Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

Junji Tsurutani1, Takashi Nitta, Tomonori Hirashima, Takefumi Komiya, Hisao Uejima, Hirohito Tada, Negoro Syunichi, Aritomo Tohda, Masahiro Fukuoka, Kazuhiko Nakagawa.   

Abstract

Reverse transcription polymerase chain reaction (RT-PCR) single-strand conformation polymorphism analysis was used to detect topoisomerase I (top1) mutations in total RNA from 16 specimens that were excised during surgery from eight patients with non-small cell lung cancer (NSCLC) who had received preoperative chemotherapy consisting of irinotecan (CPT-11) and cisplatin. PCR single-strand conformation polymorphism and subsequent DNA sequencing analysis showed two nucleotide substitutions resulting in Trp736stop (TGG to TGA) and Gly737Ser (GGT to AGT) in one tumor specimen. The mutations were located near a site in top1 that was previously reported to harbor a mutation in the human lung cancer cell line PC7/CPT, which was selected for CPT resistance. These results demonstrate that mutations in top1 occur after chemotherapy with CPT-11 in NSCLC patients and suggest that development of resistance to CPT-11 in some patients may involve mutation of top1. However, the significance of top1 mutations to CPT resistance needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844605     DOI: 10.1016/s0169-5002(01)00425-1

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

1.  The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.

Authors:  E A Gaffney
Journal:  J Math Biol       Date:  2003-10-27       Impact factor: 2.259

Review 2.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

3.  Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.

Authors:  Bin Wei; Jiru Wang; Xiaohui Zhang; Zhaoye Qian; Jingjing Wu; Yuan Sun; Qin Han; Li Wan; Jing Zhu; Yong Gao; Xiaofei Chen
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 4.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

Authors:  Murugesan K Gounder; Ahamed S Nazar; Ahamed Saleem; Pooja Pungaliya; Diptee Kulkarni; Richard Versace; Eric H Rubin
Journal:  Invest New Drugs       Date:  2007-10-18       Impact factor: 3.850

6.  Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent.

Authors:  Tomoya Fukui; Hisashi Mitsufuji; Masaru Kubota; Hidenori Inaoka; Minoru Hirose; Keiichi Iwabuchi; Noriyuki Masuda; Hirosuke Kobayashi
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

7.  New Topoisomerase I mutations are associated with resistance to camptothecin.

Authors:  Céline Gongora; Nadia Vezzio-Vie; Sandie Tuduri; Vincent Denis; Annick Causse; Céline Auzanneau; Gwenaëlle Collod-Beroud; Arnaud Coquelle; Philippe Pasero; Philippe Pourquier; Pierre Martineau; Maguy Del Rio
Journal:  Mol Cancer       Date:  2011-05-27       Impact factor: 27.401

8.  Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.

Authors:  F Moisan; M Longy; J Robert; V Le Morvan
Journal:  Br J Cancer       Date:  2006-09-19       Impact factor: 7.640

9.  FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.

Authors:  David Westover; Xiang Ling; Hong Lam; Jacob Welch; Chunyang Jin; Celine Gongora; Maguy Del Rio; Mansukh Wani; Fengzhi Li
Journal:  Mol Cancer       Date:  2015-04-28       Impact factor: 27.401

10.  Quantitative interactome analysis reveals a chemoresistant edgotype.

Authors:  Juan D Chavez; Devin K Schweppe; Jimmy K Eng; Chunxiang Zheng; Alex Taipale; Yiyi Zhang; Kohji Takara; James E Bruce
Journal:  Nat Commun       Date:  2015-08-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.